公司资料
ProMIS Neurosciences 股价、新闻与催化剂
- 股票代码:
- PMN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Canada and listed in the U
股票表现
14.66 USD (-1.35%)
收盘价
最后更新: 2026年8月17日
91M USD
市值
股价为何变动
As of Aug 17, 2026, PMN closed down 1.35% at $14.66. No new same-company headline was identified in the current news window.
公司概览
Misfolded Protein Therapeutics
ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease.
PMN310
PMN310 targets toxic amyloid-beta oligomers while seeking to avoid binding monomers and plaque, potentially reducing off-target immune effects.
PRECISE-AD
The fully enrolled Phase 1b PRECISE-AD study evaluates PMN310 in patients with Alzheimer’s disease using safety, imaging, and biomarker measures.
未来催化剂
- Twelve-month unblinded topline results from the Phase 1b PRECISE-AD study of PMN310 in the first quarter of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。